Home › Calculator › IPHA Dividend Calculator 2026
IPHA Dividend DRIP Calculator 2026
106.95% YieldHealthcareInnate Pharma S.A. · NASDAQ
Price: $1.87 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IPHA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your IPHA snowball 📈
$10,000 in IPHA → $1561162887962.35M in 10 years · $129,978,226,039,817,780.00/month
About Innate Pharma S.A. (IPHA) — Dividend Analysis 2026
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Compare IPHA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IPHA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IPHA position with:
🌍 IPHA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IPHA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 106.95% | 104.15% | $10,695 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 90.91% | 88.11% | $9,091 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 85.56% | 82.76% | $8,556 / yr |
| 🇬🇧 UK ISA | 0% | 106.95% | 104.15% | $10,695 / yr |
| 🇬🇧 UK Taxable | 8.75% | 97.59% | 94.79% | $9,759 / yr |
| 🇨🇦 TFSA | 0% | 106.95% | 104.15% | $10,695 / yr |
| 🇨🇦 CA Taxable | 25% | 80.21% | 77.41% | $8,021 / yr |
| 🇦🇺 Super (pension) | 15% | 90.91% | 88.11% | $9,091 / yr |
| 🇦🇺 AU Taxable | 30% | 74.86% | 72.06% | $7,486 / yr |
| 🇩🇪 DE Taxable | 26.375% | 78.74% | 75.94% | $7,874 / yr |
| 🇫🇷 FR Taxable | 30% | 74.86% | 72.06% | $7,486 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IPHA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IPHA Dividend Payment Schedule
IPHA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 IPHA vs Healthcare Benchmarks
How IPHA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IPHA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IPHA Insider Activity
No recent SEC filings reported in the last 90 days.Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IPHA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Innate Pharma S.A. (IPHA) is currently trading at $1.87, 69% below its 52-week high. The current dividend yield is 106.95% based on an annual payout of $2.00 per share.
IPHA (Innate Pharma S.A.) — 106.95% Dividend Yield Analysis
Innate Pharma S.A. (IPHA) is a healthcare stock currently trading at $1.87 with a dividend yield of 106.95%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (106.95%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IPHA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.